01—Abstract
Summary
Summary of the 10-Q filed July 25, 2024. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. reported a strong second quarter for 2024, demonstrating robust growth and profitability.
Revenue increased by 15% year-over-year to $1.004 billiona, driven by sustained demand for their continuous glucose monitoring (CGM) systems. Gross profit also grew by 15% to $626.7 million, indicating effective cost management alongside sales expansion. The company achieved significant operating income growth of 23%, reaching $158.0 million, and net income surged by 24% to $143.5 million, highlighting operational efficiency and strong earnings power.
The company's balance sheet remains healthy, with cash, cash equivalents, and short-term marketable securities totaling $3.12 billionb, providing substantial liquidity. Cash flow from operations was particularly strong, showing a 47% increase year-over-year for the quarter, underscoring the company's ability to generate substantial cash from its core business activities. Furthermore, DexCom announced a new $750 million share repurchase program, signaling confidence in its financial position and commitment to returning value to shareholders.
02—Key points
Key Highlights
- Revenue increased by 15% to $1.004 billion for the three months ended June 30, 2024, compared to $871.3 million in the prior year period.
- Net income grew by 24% to $143.5 million for the three months ended June 30, 2024, up from $115.9 million in the prior year period.
- Diluted net income per share rose to $0.35 from $0.28 in the same period last year, a 25% increase.
- Operating income saw a substantial increase of 23% year-over-year, reaching $158.0 million.
- Cash flow from operating activities for the six months ended June 30, 2024, was $488.6 million, an increase from $345.7 million in the prior year period.
- The company ended the quarter with $3.12 billion in cash, cash equivalents, and short-term marketable securities, indicating strong liquidity.
- DexCom announced a new $750 million share repurchase program authorized in July 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Dexcom Inc kept $0.14.
- Revenue$1.00B100.0%
- Cost of revenue−$377.6M37.6%
- Gross profit$626.7M62.4%
- Operating costs−$468.7M46.7%
- Operating income$158.0M15.7%
- Interest, other & tax−$14.5M1.4%
- Net income$143.5M14.3%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 25, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $1.00B$871.30M | +15.3% |
| Cost of Revenue | $377.60M$324.90M | +16.2% |
| Gross Profit | $626.70M$546.40M | +14.7% |
| R&D Expenses | $136.00M$119.30M | +14.0% |
| SG&A Expenses | $332.70M$299.00M | +11.3% |
| Operating Expenses | $468.70M$418.30M | +12.0% |
| Operating Income | $158.00M$128.10M | +23.3% |
| Interest Expense | $3.80M$5.00M | −24.0% |
| Net Income | $143.50M$115.90M | +23.8% |
| EPS (Basic) | $0.36$0.30 | +20.0% |
| EPS (Diluted) | $0.35$0.28 | +25.0% |
| Shares Outstanding (Basic) | 399.20M386.70M | +3.2% |
| Shares Outstanding (Diluted) | 416.80M431.50M | −3.4% |
05—Questions
Frequently Asked Questions
What was DexCom's revenue growth in the reported quarter?
DexCom reported a 15% increase in revenue for the three months ended June 30, 2024, reaching $1.004 billion, up from $871.3 million in the same period last year. For the six-month period, revenue grew by 19% to $1.925 billion.
How did DexCom's profitability perform in this quarter?
Profitability showed strong improvement. Net income for the second quarter of 2024 increased by 24% to $143.5 million, with diluted earnings per share rising 25% to $0.35. Operating income also grew significantly by 23% to $158.0 million.
What is the company's current financial health and liquidity position?
DexCom maintains a strong liquidity position, ending the quarter with $3.12 billion in cash, cash equivalents, and short-term marketable securities. Operating cash flow was robust, generating $488.6 million for the six-month period, demonstrating the company's ability to fund its operations and growth.
Are there any significant legal proceedings that could impact the company?
DexCom is involved in ongoing patent litigation with Abbott Diabetes Care. While a jury returned a mixed verdict in one U.S. case, Dexcom is challenging the finding of infringement and believes it is not probable that an unfavorable outcome leading to a material loss will occur. However, due to the complexity and ongoing nature of multiple international and U.S. patent disputes, the ultimate outcome of all litigation matters remains uncertain.
What are the key updates regarding capital allocation and future plans?
In July 2024, DexCom's Board of Directors authorized a new share repurchase program of up to $750 million, indicating a commitment to returning capital to shareholders. The company continues to invest in research and development for future product generations and expanding its market reach, including for non-insulin dependent Type 2 diabetes patients.
06—Continue